SCHEMBL4313552

SCHEMBL4313552

CC(=O)Nc1ccc(C(=O)Nc2ccccc2/C=C/c2n[nH]c3ccccc23)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.42
EPHB3 P54753 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
FGFR1 P11362 4/20 0.39
YTHDC1 Q96MU7 1/20 0.38
AURKA O14965 2/20 0.37
AURKB Q96GD4 2/20 0.37
MAPT P10636 2/20 0.37
FLT3 P36888 3/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCNA1 P78396 1/20 0.37
KDM4E B2RXH2 2/20 0.36
BMPR1B O00238 1/20 0.36
PLK4 O00444 1/20 0.36
STK25 O00506 1/20 0.36
CIT O14578 1/20 0.36
RIOK3 O14730 1/20 0.36
CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313556 1.00 KDR (0.42) KDREPHB3CASP3SENP8FGFR1
SCHEMBL4314953 0.90 KDR (0.41) KDREPHB3CASP3SENP8FGFR1
SCHEMBL4314947 0.90 KDR (0.41) KDREPHB3CASP3SENP8FGFR1
SCHEMBL4319176 0.89 KDR (0.51) KDREPHB3CASP3SENP8FGFR1
SCHEMBL4319184 0.89 KDR (0.51) KDREPHB3CASP3SENP8FGFR1
SCHEMBL4322679 0.89 ALDH1A1 (0.42) KDREPHB3CASP3SENP8AURKA
SCHEMBL4322671 0.89 ALDH1A1 (0.42) KDREPHB3CASP3SENP8AURKA
SCHEMBL4313818 0.87 SMN1; SMN2 (0.46) KDREPHB3FGFR1AURKAAURKB
SCHEMBL4313824 0.87 SMN1; SMN2 (0.46) KDREPHB3FGFR1AURKAAURKB
SCHEMBL4317526 0.85 FGFR1 (0.48) KDREPHB3FGFR1YTHDC1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDR 75/4885EPHB3 3547/4885CASP3 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.